ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO586

Congenital Nephrotic Syndrome in the Amish and Mennonite Population of Central Pennsylvania

Session Information

  • Pediatric Nephrology - II
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1800 Pediatric Nephrology


  • Kim, Hannah, Penn State College of Medicine, Hershey, Pennsylvania, United States

Group or Team Name

  • Penn State Children's Hospital and Division of Pediatric Nephrology and Hypertension

Pennsylvania has the largest Amish/Mennonite population in the United States. The Amish/Mennonites accept beliefs that restrict participation in larger American society and thus have increased risk for certain genetic diseases including congenital nephrotic syndrome (CNS). We aim to describe the CNS population at Penn State Children’s Hospital.


Clinical characteristics of the known CNS population at Penn State Children’s Hospital were assessed using a retrospective electronic medical record review. An individual was defined as being part of, or historically part of, the Amish or Mennonite population by self-disclosure. Characteristics were summarized using medians (interquartile ranges) or proportions. Kaplan-Meier curves and Log-rank tests were used to evaluate time to end-stage kidney disease as defined by time to end-stage kidney disease (ESKD).


25 patients were identified at Penn State Children’s Hospital over the last 30 years with a diagnosis of CNS (Table 1). Of those patients, 80% identified as Amish or Mennonite. The majority had either NPHS1 or NPHS2 mutations. The median time to ESKD was at 3 years of age (Figure 1). The median time to ESKD was faster for those with NPHS1 as compared to those with NPHS2 mutations (3 vs. 6 years, p<0.001).


The majority of children were of Amish or Mennonite background with ESKD in the first few years of life. Most had associated hypothyroidism, but the incidence of other complications including thromboses and serious bacterial infections was low.

Table 1. Clinical Characteristics

Figure 1. Time to ESKD